Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Washington
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
University Hospital Heidelberg
Fred Hutchinson Cancer Center
NRG Oncology
Massachusetts General Hospital
Mayo Clinic
Mayo Clinic
University of Michigan Rogel Cancer Center
Mayo Clinic
University of Washington
Odense University Hospital
Shanghai Proton and Heavy Ion Center